Patent Inventorship: Best Practices for Determination and Correction
Distinguishing Between Inventor and Contributor; Navigating Joint Inventorship, Disclosure of Ownership, Real Party in Interest
Recording of a 90-minute premium CLE video webinar with Q&A
This CLE course will guide patent counsel in identifying and determining inventorship and offer best practices for correcting errors regarding inventorship. Our experienced panel will provide perspectives gained from working with the AIA since its passage and outline lessons from recent court decisions.
Outline
- Inventorship determination
- Sole vs. joint
- Document review
- Questions to ask to determine inventorship
- Naming applicant
- Court treatment
- Impact of AIA (or lack thereof)
- Real party in interest
- Correcting inventorship
- Pre vs. post-filing
- Provisional application
- Best practices
Benefits
The panel will review these and other key issues:
- What information does counsel need to determine inventorship?
- What are the steps for counsel when inventorship must be corrected?
- What is the AIA's impact on inventorship determination?
Faculty

Jill K. MacAlpine, Ph.D.
Partner
Finnegan Henderson Farabow Garrett & Dunner
Dr. MacAlpine practices patent procurement, due diligence investigations, opinion work, and client counseling,... | Read More
Dr. MacAlpine practices patent procurement, due diligence investigations, opinion work, and client counseling, primarily in the chemical and pharmaceutical areas. She has extensive experience in handling patent matters before the U.S. Patent and Trademark Office (USPTO), including post-grant proceedings specifically IPRs, appeals, and oral hearings at the PTAB; drafting and prosecution of patent applications; reissue and reexamination proceedings; and interferences.
Close
Dr. Amanda K. Murphy, Ph.D.
Partner
Finnegan Henderson Farabow Garrett & Dunner
Dr. Murphy focuses her practice on client counseling and patent prosecution for a range of clients. She prepares new... | Read More
Dr. Murphy focuses her practice on client counseling and patent prosecution for a range of clients. She prepares new patent applications, prosecutes U.S. and foreign applications, and represents applicants at appeals and oral hearings before the PTAB. She has experience in prosecuting inter partes and ex partes reexamination applications, reissue applications, and patent term extension applications for approved pharmaceuticals, including obtaining supplemental protection certificates in Europe.
Close
Emily R. Gabranski
Attorney
Finnegan Henderson Farabow Garrett & Dunner
Ms. Gabranski focuses her practice on patent litigation, primarily in the biotechnology and pharmaceutical areas. She... | Read More
Ms. Gabranski focuses her practice on patent litigation, primarily in the biotechnology and pharmaceutical areas. She assists with Hatch-Waxman litigation related to Abbreviated New Drug Applications (ANDA) and post-grant proceedings before the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO). Prior to joining Finnegan, she conducted research in cellular and molecular neurobiology. Her research focused on transmitter modulation of neuronal network interactions. She co-authored two peer-reviewed publications in scientific journals and presented her research at the Society for Neuroscience annual meeting.
Close
Kathryn R. Judson
Attorney
Finnegan Henderson Farabow Garrett & Dunner
Ms. Judson focuses on complex patent litigation involving pharmaceuticals, chemicals, and biotechnology. Her practice... | Read More
Ms. Judson focuses on complex patent litigation involving pharmaceuticals, chemicals, and biotechnology. Her practice includes Hatch-Waxman litigation related to Abbreviated New Drug Applications (ANDA) and post-grant proceedings before the U.S. Patent and Trademark Office (USPTO). She also has experience with renewable energy technologies.
Close